Illumina stock $ILMN has fallen around 50% over the past rolling year as their GRAIL acquisition screeches to a halt. European regulators may soon demand that Illumina divest GRAIL and the company has already said they're pursuing strategic alternatives. It's just another failed M&A event for Illumina which also wasn't able to make their proposed acquisition of PacBio happen. Speaking of which, Illumina's long-read technology - Infinity - has now been renamed to Complete Long-Reads (CLR) and we'll need to wait until next year to see if the life sciences community is buying it.
RESEARCH PIECES USED IN THIS VIDEO:
1. Illumina Stock Falls on GRAIL Acquisition Fail
[ Ссылка ]
2. What’s Up With Illumina’s Acquisition of GRAIL?
[ Ссылка ]
ABOUT US:
This video is brought to you by Nanalyze, a media and research firm founded by finance professionals with decades of experience. We share insights about #DisruptiveTechnology #stocks in a language that is future-proof and easy to understand.
Read all the Nanalyze Premium articles you'd like for free! Sign up for a 30-day trial of our monthly subscription with no strings attached: [ Ссылка ]
DISCLAIMER: Our content is intended to be used and must be used for informational purposes only. It is very important to do your own analysis before making any investment based on your own personal circumstances. You should take independent financial advice from a professional in connection with, along with independently researching and verifying, any information contained within our YouTube videos or on our website, whether for the purpose of making an investment or otherwise.
#biotechnology #technology #pacbio #lifesciences
